1244 — 3D Medicines Income Statement
0.000.00%
Last trade - 00:00- HK$1.61bn
- HK$762.43m
- CNY634.95m
Annual income statement for 3D Medicines, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Interim Report | PRESS |
| Standards: | IFRS | IFRS | — | — |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 60.3 | 567 | 635 |
| Cost of Revenue | ||||
| Gross Profit | 0 | 56 | 525 | 586 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 308 | 566 | 959 | 1,190 |
| Operating Profit | -308 | -505 | -392 | -555 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -635 | -1,462 | -1,052 | -562 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -635 | -1,462 | -1,052 | -563 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -635 | -1,434 | -1,024 | -525 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -635 | -1,434 | -1,024 | -525 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -2.47 | -5.51 | -3.89 | -2.3 |